Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Precision Therapy in Refractory Tumor (Long March Pathway)
NCT03239015Phase 2Unknown
- Start
- Jan 2017
- Primary completion
- Jun 2023
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of gefitinib, erlotinib, afatinib, trastuzumab, olaparib in solid tumor. Status: unknown.
02
Drugs
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03239015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03239015.